New research reveals that patients who discontinue new weight-loss injections like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a major health publication points out that while obese individuals can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing such treatments must be cognizant of the risk of rapid weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to original weight in about a year and a half.
Comparing Treatments
The study, which examined 37 of studies involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
The team point out that people who lose weight through dieting generally have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the mode of action of the injections explains the accelerated regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating far more likely."
A Lifelong Condition?
Medical guidelines advise the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of relapse, the therapy might need to be life-long.
This opinion is echoed by drug manufacturers, who say that the results "highlight the persistent character of excess weight," similar to managing conditions like hypertension.
User Accounts
Users who have discontinued the medication explain a sudden return of cravings.
"It was like a switch flipping and I was suddenly starving," recalled an individual.
This challenge is compounded if users have not adopted lasting lifestyle or habit modifications during therapy.
Widespread Interest
Figures suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among women than males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss hinges on ongoing lifestyle management.
